Michael A. Vogelbaum

1998–2025 年に発表

別表記
Michael A Vogelbaum
179
論文数
31,284
被引用数
94
h 指数
172
i10 指数

被引用数

Michael A. Vogelbaum の年別被引用数1993 年: 被引用 2 件1999 年: 被引用 2 件2000 年: 被引用 4 件2001 年: 被引用 4 件2002 年: 被引用 4 件2003 年: 被引用 9 件2004 年: 被引用 10 件2005 年: 被引用 14 件2006 年: 被引用 15 件2007 年: 被引用 20 件2008 年: 被引用 46 件2009 年: 被引用 42 件2010 年: 被引用 78 件2011 年: 被引用 123 件2012 年: 被引用 125 件2013 年: 被引用 167 件2014 年: 被引用 220 件2015 年: 被引用 266 件2016 年: 被引用 262 件2017 年: 被引用 332 件2018 年: 被引用 269 件2019 年: 被引用 1,025 件2020 年: 被引用 1,335 件2021 年: 被引用 1,356 件2022 年: 被引用 1,202 件2023 年: 被引用 1,009 件2024 年: 被引用 1,784 件2025 年: 被引用 1,010 件2026 年: 被引用 46 件1994〜1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,593 件、この内訳の 27.5%中国: 引用元論文 1,250 件、この内訳の 9.6%ドイツ: 引用元論文 1,048 件、この内訳の 8%イギリス: 引用元論文 686 件、この内訳の 5.3%イタリア: 引用元論文 658 件、この内訳の 5%フランス: 引用元論文 550 件、この内訳の 4.2%カナダ: 引用元論文 508 件、この内訳の 3.9%オランダ: 引用元論文 506 件、この内訳の 3.9%スイス: 引用元論文 444 件、この内訳の 3.4%スペイン: 引用元論文 331 件、この内訳の 2.5%日本: 引用元論文 292 件、この内訳の 2.2%韓国: 引用元論文 265 件、この内訳の 2%
0%27.5%その他 22.5%

分野

  • Medicine70.4%
  • Biochemistry, Genetics and Molecular Biology13%
  • Immunology and Microbiology5.9%
  • Neuroscience3.1%
  • Computer Science2.1%
  • Engineering1.9%
  • その他3.6%

トピック

  • Glioma Diagnosis and Treatment17.5%
  • Brain Metastases and Treatment8.4%
  • Meningioma and schwannoma management4.2%
  • Radiomics and Machine Learning in Medical Imaging3.2%
  • Immune cells in cancer2.3%
  • Lung Cancer Research Studies2.1%
  • その他62.3%

共著者

全論文

検索で開く
  1. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2010 被引用: 3,829

  2. Federated learning enables big data for rare cancer boundary detection

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John W. Garrett, Matthew Larson, Robert Jeraj, Stuart Currie, Russell Frood, Kavi Fatania, Raymond Y. Huang, Ken Chang, Carmen Balañá, Jaume Capellades, Josep Puig, Johannes Trenkler, Josef Pichler, Georg Necker, Andreas Haunschmidt, Stephan Meckel, Gaurav Shukla, Spencer Liem, Gregory S. Alexander, Joseph S. Lombardo, Joshua D. Palmer, Adam E. Flanders, Adam P. Dicker, Haris I. Sair, Craig Jones, Archana Venkataraman, Meirui Jiang, Tiffany Y. So, Cheng Chen, Pheng‐Ann Heng, Qi Dou, Michal Kozubek, Filip Lux, Jan Michálek, Petr Matula, Miloš Keřkovský, Tereza Kopřivová, Marek Dostál, Václav Vybíhal, Michael A. Vogelbaum, J. Ross Mitchell, Joaquim M. Farinhas, Joseph A. Maldjian, Chandan Ganesh Bangalore Yogananda, Marco C. Pinho, Divya Reddy, James Holcomb, Benjamin Wagner, Benjamin M. Ellingson, Timothy F. Cloughesy, Catalina Raymond, Talia C. Oughourlian, Akifumi Hagiwara, Chencai Wang, Minh‐Son To, Sargam Bhardwaj, Chee Chong, Marc Agzarian, Alexandre X. Falcão, Samuel Botter Martins, Bernardo Corrêa de Almeida Teixeira, F Sprenger, David Menotti, Diego Rafael Lucio, Pamela LaMontagne, Daniel S. Marcus, Benedikt Wiestler, Florian Kofler, Ivan Ezhov, Marie Metz ほか 179 名 - Nature Communications 2022 被引用: 340

  3. A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 被引用: 2,793

  4. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 462

  5. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Paul C. Boutros, Joan M. Robbins, Warren Mason, Adam M. Sonabend, Roger Stupp, Juàn Fueyo, Candelaria Gomez‐Manzano, Frederick F. Lang, Gelareh Zadeh - Nature Medicine 2023 被引用: 270

  6. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 798

  7. Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma

    著者: , , , , , , , , , , , , , , , , - Immunity 2024 被引用: 260

  8. Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Neuro-Oncology 2022 被引用: 343

  9. Response assessment criteria for brain metastases: proposal from the RANO group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 被引用: 1,088

  10. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Iris de Heer, Kenneth Aldape, Robert B. Jenkins, Hendrikus J. Dubbink, Johan M. Kros, Pieter Wesseling, Sarah Nuyens, Vassilis Golfinopoulos, Thierry Gorlia, Pim J. French, Brigitta G. Baumert - The Lancet Oncology 2021 被引用: 327

  11. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Walter J. Curran, Minesh P. Mehta - Neuro-Oncology 2022 被引用: 147

  12. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Neuro-Oncology 2015 被引用: 665

  13. Convection-enhanced drug delivery for glioblastoma: a review

    著者: , , , - Journal of Neuro-Oncology 2021 被引用: 156

  14. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas

    著者: , , , , , , , , , , , , , - Neuro-Oncology 2016 被引用: 745

  15. Evidence-based recommendations on categories for extent of resection in diffuse glioma

    著者: , , , , , , , , - European Journal of Cancer 2021 被引用: 208

  16. Response Assessment in Neuro-Oncology Clinical Trials

    著者: , , , , , - Journal of Clinical Oncology 2017 被引用: 442

  17. Liquid biopsy in gliomas: A RANO review and proposals for clinical applications

    著者: , , , , , , , , , , , , , , , , , , - Neuro-Oncology 2022 被引用: 134

  18. Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion

    著者: , , , , , , , , , , , , , , , , , , , , , - Stem Cells 2016 被引用: 253

  19. Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression

    著者: , , , , , , , , , , , , , , , , - Frontiers in Immunology 2020 被引用: 157

  20. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Roger Stupp, Ken Aldape, Robert B. Jenkins, Hendrikus J. Dubbink, Winand N.M. Dinjens, Pieter Wesseling, Sarah Nuyens, Vassilis Golfinopoulos, Thierry Gorlia, Wolfgang Wick, Johan M. Kros - The Lancet 2017 被引用: 397

  21. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group

    著者: , , , , , , , , , , , , , , , , , - Neuro-Oncology 2018 被引用: 205

  22. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review

    著者: , , , , , , , , , - Journal of neurosurgery 2014 被引用: 696

  23. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma

    著者: , , , , , , , , - Neuro-Oncology 2011 被引用: 356

  24. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma

    著者: , , , , , , , , , , , , , , , , - Neuro-Oncology 2010 被引用: 481